Genscript Biotech First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 09/01 01:53

Genscript Biotech (HKG:1548) First Half 2024 Results

Key Financial Results

  • Revenue: US$561.4m (up 44% from 1H 2023).
  • Net loss: US$175.1m (loss widened by 87% from 1H 2023).
  • US$0.083 loss per share (further deteriorated from US$0.044 loss in 1H 2023).
earnings-and-revenue-growth
SEHK:1548 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genscript Biotech Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Life Sciences industry in Hong Kong.

Performance of the Hong Kong Life Sciences industry.

The company's shares are down 1.7% from a week ago.

Risk Analysis

Be aware that Genscript Biotech is showing 1 warning sign in our investment analysis that you should know about...